nach oben

Erschienen in:

15.03.2018 | Brief Report

Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas—differences in mutation profiles in epithelial-derived oropharyngeal neoplasms

verfasst von: Stephan Bartels, Akinyele Adisa, Timothy Aladelusi, Juliana Lemound, Angelika Stucki-Koch, Sami Hussein, Hans Kreipe, Christian Hartmann, Ulrich Lehmann, Kais Hussein

Erschienen in: Virchows Archiv | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to evaluate the mutation profile of BRAF wild-type craniopharyngiomas and ameloblastomas. Pre-screening by immunohistochemistry and pyrosequencing for identifying BRAF wild-type tumors was performed on archived specimens of ameloblastic tumors (n = 20) and craniopharyngiomas (n = 62). Subsequently, 19 BRAF wild-type tumors (nine ameloblastic tumors and ten craniopharyngiomas) were analyzed further using next-generation sequencing (NGS) targeting hot spot mutations of 22 cancer-related genes. Thereby, we found craniopharyngiomas mainly CTNNB1 mutated (8/10), including two FGFR3/CTNNB1-double mutated tumors. Ameloblastic tumors were often FGFR2 mutated (4/9; including one FGFR2/TP53/PTEN-triple mutated case) and rarely CTNNB1/TP53-double mutated (1/9) and KRAS-mutated (1/9). In the remaining samples, no mutation could be detected in the 22 genes under investigation. In conclusion, mutation profiles of BRAF wild-type craniopharyngiomas and ameloblastomas share mutations of FGFR genes and have additional mutations with potential for targeted therapy.

Nur mit Berechtigung zugänglich

Schiebler TH, Schmidt W, Zilles K (1995) Anatomie. Springer, BerlinCrossRef

Sekine S, Takata T, Shibata T, Mori M, Morishita Y, Noguchi M, Uchida T, Kanai Y, Hirohashi S (2004) Expression of enamel proteins and LEF1 in adamantinomatous craniopharyngioma: evidence for its odontogenic epithelial differentiation. Histopathology 45:573–579CrossRefPubMed

Negoto T, Sakata K, Aoki T, Orito K, Nakashima S, Hirohata M, Sugita Y, Morioka M (2015) Sequential pathological changes during malignant transformation of a craniopharyngioma: a case report and review of the literature. Surg Neurol Int 6:50CrossRefPubMedPubMedCentral

Li J, DU H, Li P, Zhang J, Tian W, Tang W (2014) Ameloblastic carcinoma: an analysis of 12 cases with a review of the literature. Oncol Lett 8:914–920CrossRefPubMedPubMedCentral

Heikinheimo K, Kurppa KJ, Elenius K (2015) Novel targets for the treatment of ameloblastoma. J Dent Res 94:237–240CrossRefPubMedPubMedCentral

Gomes CC, Diniz MG, Gomez RS (2014) Progress towards personalized medicine for ameloblastoma. J Pathol 232:488–491CrossRefPubMed

Gump JM, Donson AM, Birks DK, Amani VM, Rao KK, Griesinger AM, Kleinschmidt-DeMasters BK, Johnston JM, Anderson RC, Rosenfeld A, Handler M, Gore L, Foreman N, Hankinson TC (2015) Identification of targets for rational pharmacological therapy in childhood craniopharyngioma. Acta Neuropathol Commun 3:30CrossRefPubMedPubMedCentral

Kurppa KJ, Catón J, Morgan PR, Ristimäki A, Ruhin B, Kellokoski J, Elenius K, Heikinheimo K (2014) High frequency of BRAF V600E mutations in ameloblastoma. J Pathol 232:492–498CrossRefPubMedPubMedCentral

Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS, Elenitoba-Johnson KS, Betz BL (2014) Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res 20:5517–5526CrossRefPubMed

10.

Pakneshan S, Salajegheh A, Smith RA, Lam AK (2013) Clinicopathological relevance of BRAF mutations in human cancer. Pathology 45:346–356CrossRefPubMed

11.

Brastianos PK, Taylor-Weiner A, Manley PE, Jones RT, Dias-Santagata D, Thorner AR, Lawrence MS, Rodriguez FJ, Bernardo LA, Schubert L, Sunkavalli A, Shillingford N, Calicchio ML, Lidov HG, Taha H, Martinez-Lage M, Santi M, Storm PB, Lee JY, Palmer JN, Adappa ND, Scott RM, Dunn IF, Laws ER Jr, Stewart C, Ligon KL, Hoang MP, Van Hummelen P, Hahn WC, Louis DN, Resnick AC, Kieran MW, Getz G, S S (2014) Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 46:161–165CrossRefPubMedPubMedCentral

12.

Sekine S, Sato S, Takata T, Fukuda Y, Ishida T, Kishino M, Shibata T, Kanai Y, Hirohashi S (2003) Beta-catenin mutations are frequent in calcifying odontogenic cysts, but rare in ameloblastomas. Am J Pathol 163:1707–1712CrossRefPubMedPubMedCentral

13.

Bartels S, Lehmann U (2015) Analysis of mutational hotspots in routinely processed bone marrow trephines by pyrosequencing®. Methods Mol Biol 1315:103–114CrossRefPubMed

14.

Bartels S, Schipper E, Hasemeier B, Kreipe H, Lehmann U (2016) Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms. Oncotarget 7:30084–30093CrossRefPubMedPubMedCentral

15.

Lemound J, Schenk M, Keller G, Stucki-Koch A, Witting S, Kreipe H, Hussein K (2017) Cytogenetic and immunohistochemical biomarker profiling of therapy-relevant factors in salivary gland carcinomas. J Oral Pathol Med 45:655–663CrossRef

16.

Diniz MG, Duarte AP, Villacis RA, Guimarães BV, Duarte LC, Rogatto SR, Gomez RS, Gomes CC (2016) Rare copy number alterations and copy-neutral loss of heterozygosity revealed in ameloblastomas by high-density whole-genome microarray analysis. J Oral Pathol Med 46:371–376. https://doi.org/10.1111/jop.12505 CrossRefPubMed

17.

Brastianos PK, Shankar GM, Gill CM, Taylor-Weiner A, Nayyar N, Panka DJ, Sullivan RJ, Frederick DT, Abedalthagafi M, Jones PS, Dunn IF, Nahed BV, Romero JM, Louis DN, Getz G, Cahill DP, Santagata S, Curry WT Jr, Barker FG 2nd (2015) Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. J Natl Cancer Inst 108:djv310CrossRefPubMedPubMedCentral

18.

Tan S, Pollack JR, Kaplan MJ, Colevas AD, West RB (2016) BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response. Oral Surg Oral Med Oral Pathol Oral Radiol 122:e5–e7CrossRefPubMed

19.

Kaye FJ, Ivey AM, Drane WE, Mendenhall WM, Allan RW (2014) Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst 107:378CrossRefPubMed

20.

Hussain I, Eloy JA, Carmel PW, Liu JK (2013) Molecular oncogenesis of craniopharyngioma: current and future strategies for the development of targeted therapies. J Neurosurg 119:106–112CrossRefPubMed

21.

Gomes DC, Jamra SA, Leal LF, Colli LM, Campanini ML, Oliveira RS, Jr Martinelli CE, Elias PC, Moreira AC, Machado HR, Saggioro F, Neder L, Castro M, Antonini SR (2015) Sonic hedgehog pathway is upregulated in adamantinomatous craniopharyngiomas. Eur J Endocrinol 172:603–608CrossRefPubMed

22.

Katoh M (2016) FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med 38:3–15CrossRefPubMedPubMedCentral

23.

Oikonomou E, Koustas E, Goulielmaki M, Pintzas A (2014) BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget 5:11752–11777CrossRefPubMedPubMedCentral

Titel: Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas—differences in mutation profiles in epithelial-derived oropharyngeal neoplasms
verfasst von: Stephan Bartels
Akinyele Adisa
Timothy Aladelusi
Juliana Lemound
Angelika Stucki-Koch
Sami Hussein
Hans Kreipe
Christian Hartmann
Ulrich Lehmann
Kais Hussein
Publikationsdatum: 15.03.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 6/2018
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-018-2323-3

Neu im Fachgebiet Pathologie

Open Access 15.04.2024 | Biomarker | Schwerpunkt: Next Generation Pathology

Springer Medizin

Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas—differences in mutation profiles in epithelial-derived oropharyngeal neoplasms

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer

Elastic stains in the evaluation of DCIS with comedo necrosis in breast cancers

Miniseries of reviews: gynecological pathology

Extra-axial chordoma: a clinicopathologic analysis of six cases

Pathologic significance of AKT, mTOR, and GSK3β proteins in oral squamous cell carcinoma-affected patients

Pathologist’s assistant (PathA) and his/her role in the surgical pathology department: a systematic review and a narrative synthesis

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie